First Time Loading...

Centogene NV
NASDAQ:CNTG

Watchlist Manager
Centogene NV Logo
Centogene NV
NASDAQ:CNTG
Watchlist
Price: 0.71 USD 2.9%
Updated: Mar 29, 2024

Intrinsic Value

CNTG's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical c... [ Read More ]

The intrinsic value of one CNTG stock under the Base Case scenario is 6.7 USD. Compared to the current market price of 0.71 USD, Centogene NV is Undervalued by 89%.

Key Points:
CNTG Intrinsic Value
Base Case
6.7 USD
Undervaluation 89%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Centogene NV

Backtest CNTG Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CNTG stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Centogene NV

Current Assets 38.9m
Cash & Short-Term Investments 14.2m
Receivables 17.9m
Other Current Assets 6.8m
Non-Current Assets 33m
Long-Term Investments 300k
PP&E 21.6m
Intangibles 8.2m
Other Non-Current Assets 2.9m
Current Liabilities 26.9m
Accounts Payable 7m
Other Current Liabilities 19.9m
Non-Current Liabilities 60.2m
Long-Term Debt 53.1m
Other Non-Current Liabilities 7.1m
Efficiency

Earnings Waterfall
Centogene NV

Revenue
72.1m EUR
Cost of Revenue
-42.8m EUR
Gross Profit
29.3m EUR
Operating Expenses
-86.2m EUR
Operating Income
-56.9m EUR
Other Expenses
579k EUR
Net Income
-56.3m EUR

Free Cash Flow Analysis
Centogene NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CNTG Profitability Score
Profitability Due Diligence

Centogene NV's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
Positive 3-Years Revenue Growth
Positive Gross Profit
Declining ROE
19/100
Profitability
Score

Centogene NV's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

CNTG Solvency Score
Solvency Due Diligence

Centogene NV's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Positive Net Debt
32/100
Solvency
Score

Centogene NV's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CNTG Price Targets Summary
Centogene NV

Wall Street analysts forecast CNTG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CNTG is 1.53 USD with a low forecast of 1.52 USD and a high forecast of 1.58 USD.

Lowest
Price Target
1.52 USD
113% Upside
Average
Price Target
1.53 USD
115% Upside
Highest
Price Target
1.58 USD
122% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

CNTG Price
Centogene NV

1M 1M
+1%
6M 6M
-33%
1Y 1Y
-3%
3Y 3Y
-94%
5Y 5Y
-94%
10Y 10Y
-94%
Annual Price Range
0.71
52w Low
0.63
52w High
1.64
Price Metrics
Average Annual Return -36.2%
Standard Deviation of Annual Returns 39.12%
Max Drawdown -97%
Shares Statistics
Market Capitalization 19.8m USD
Shares Outstanding 27 865 800
Percentage of Shares Shorted 0.22%

CNTG Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Centogene NV Logo
Centogene NV

Country

Germany

Industry

Biotechnology

Market Cap

19.8m USD

Dividend Yield

0%

Description

Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 808 full-time employees. The company went IPO on 2019-11-07. The company focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The firm provides the full spectrum of methods and technology for human genetics analysis. The company develops a rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450,000 patients representing around 115 different, which includes epidemiologic, phenotypic and genetic data that reflects a global population, as well as a biobank of patients’ blood samples. In addition, it is active in the research and development products for human genetics. The firm operates in Germany and the United States.

Contact

MECKLENBURG-VORPOMMERN
Rostock
Am Strande 7
+49038180113400.0
https://www.centogene.com/

IPO

2019-11-07

Employees

808

Officers

CEO & Member of Management Board
Ms. Kim Stratton
CFO, Legal & IT and Member of Management Board
Mr. Jose Miguel Coego Rios
Chief Medical & Genomic Officer and Member of Management Board
Dr. Peter Bauer M.D.
Advisor
Dr. Andrin Oswald M.D., Ph.D.
Chief Commercial Officer & GM of Pharma
Mr. Ian Rentsch

See Also

Discover More
What is the Intrinsic Value of one CNTG stock?

The intrinsic value of one CNTG stock under the Base Case scenario is 6.7 USD.

Is CNTG stock undervalued or overvalued?

Compared to the current market price of 0.71 USD, Centogene NV is Undervalued by 89%.